Tg Therapeutics (TGTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.05
- EPS estimate
- $0.31
- EPS surprise
- −83.64%
- Revenue surprise
- +4.60%
- Revenue
- $240.3M
- Revenue estimate
- $229.8M
- Reported
- Aug 3, 2026
TG Therapeutics reported Q2 2026 results on August 3, 2026. Earnings per share were $0.05, short of the $0.31 estimate by 83.64%. Revenue of $240.3 million beat the $229.8 million consensus by 4.60%. Compared with Q2 2025, EPS fell from $0.17, while revenue rose about 70% from $141.1 million. That revenue is the table high.
The record is uneven. TG Therapeutics posted a loss in every quarter from Q2 2021 through Q1 2024, except Q3 2023, and has been profitable in every quarter since. The table has no row for Q3 2022, and two quarters stand far apart from their neighbours: Q3 2023 revenue of $165.8 million and Q3 2025 EPS of $2.43. Annual EPS was $0.14 in 2024 and $2.77 in 2025, the latter including that Q3 figure. Annual revenue grew from about $329 million in 2024 to about $616 million in 2025. The company topped the EPS estimate in only seven of the last 20 quarters and missed in five of the last six.
TG Therapeutics reported Q3 between November 1 and November 4 in each of the four years shown. That points to early November 2026 for the next report. It will show whether revenue growth continues.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 3, 2026 | $0.31 | $0.05 | −83.64% | $240.3M | SEC |
| Q1 2026 | May 6, 2026 | $0.28 | $0.12 | −56.44% | $204.9M | SEC |
| Q4 2025 | Feb 26, 2026 | $0.35 | $0.14 | −60.28% | $192.6M | SEC |
| Q3 2025 | Nov 3, 2025 | $0.22 | $2.43 | +1010.10% | $161.7M | SEC |
| Q2 2025 | Aug 4, 2025 | $0.21 | $0.17 | −19.51% | $141.1M | SEC |
| Q1 2025 | May 5, 2025 | $0.17 | $0.03 | −82.53% | $120.9M | SEC |
| Q4 2024 | Mar 3, 2025 | $0.16 | $0.15 | −4.58% | $108.2M | SEC |
| Q3 2024 | Nov 4, 2024 | $0.03 | $0.02 | −33.33% | $83.9M | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.05 | $0.04 | +187.72% | $73.5M | SEC |
| Q1 2024 | May 1, 2024 | −$0.06 | −$0.07 | −16.67% | $63.5M | SEC |
| Q4 2023 | Feb 28, 2024 | −$0.10 | −$0.09 | +10.27% | $44.0M | SEC |
| Q3 2023 | Nov 1, 2023 | $0.06 | $0.73 | +1176.22% | $165.8M | SEC |
| Q2 2023 | Aug 1, 2023 | −$0.25 | −$0.34 | −35.19% | $16.1M | SEC |
| Q1 2023 | May 1, 2023 | −$0.36 | −$0.28 | +22.76% | $7.8M | SEC |
| Q4 2022 | Feb 28, 2023 | −$0.27 | −$0.39 | −43.86% | $80,000.00 | SEC |
| Q2 2022 | Aug 8, 2022 | −$0.48 | −$0.30 | +37.50% | $594,000.00 | SEC |
| Q1 2022 | May 10, 2022 | −$0.61 | −$0.51 | +16.71% | $2.0M | — |
| Q4 2021 | Mar 1, 2022 | −$0.64 | −$0.70 | −10.24% | $2.3M | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.57 | −$0.65 | −14.04% | $2.0M | SEC |
| Q2 2021 | Aug 2, 2021 | −$0.52 | −$0.59 | −13.46% | $1.5M | SEC |
Quarterly revenue
Frequently asked questions
When did Tg Therapeutics (TGTX) last report earnings?
Tg Therapeutics last reported on Aug 3, 2026, covering fiscal Q2 2026.
Did TGTX beat earnings estimates?
No. Tg Therapeutics reported EPS of $0.05 for Q2 2026 against a $0.31 estimate — a 83.64% miss.
How much revenue did TGTX report last quarter?
Tg Therapeutics reported $240.3M in revenue for Q2 2026, against a consensus estimate of $229.8M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.